Christopher R. Flowers, MD, MS, and colleagues shed light on recent updates in the treatment armamentarium for follicular lymphoma and highlight ongoing investigations of novel agents and combinations.
Current and Emerging Therapeutic Advances in Follicular Lymphoma
Matthew Lunning, DO, FACP, discusses considerations for community oncologists who treat patients with relapsed/refractory follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5